Molecular mechanisms of L-DOPA-induced dyskinesia

被引：0
作者：
Peter Jenner
机构：
[1] King's College London,
[2] Guy's Campus,undefined
[3] School of Health and Biomedical Sciences,undefined
来源：
Nature Reviews Neuroscience | 2008年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dyskinesia is a treatment-limiting side effect of dopaminergic replacement therapies in Parkinson's disease. Here Jenner discusses what we know about the molecular causes of dyskinesia induction and expression, highlighting recent findings that suggest that altered glutamatergic transmission might be important.
引用
收藏
页码：665 / 677
页数：12
相关论文
共 446 条
[1]  
Tanner CM(1999)Epidemiology of Parkinson's disease Adv. Neurol. 80 153-159
[2]  
Ben-Shlomo Y(2003)Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity Am. J. Epidemiol. 157 1015-1022
[3]  
Van Den Eeden SK(2007)Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 384-386
[4]  
Dorsey ER(2006)An update on the treatment of Parkinson's disease Mt. Sinai J. Med. 73 682-689
[5]  
Jankovic J(2007)Medical management of levodopa-associated motor complications in patients with Parkinson's disease CNS Drugs 21 677-692
[6]  
Jankovic J(2001)Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 448-458
[7]  
Stacy M(2005)Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov. Disord. 20 S11-S16
[8]  
Ahlskog JE(2002)How common are complications of Parkinson's disease? J. Neurol. 249 419-423
[9]  
Muenter MD(2004)Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch. Neurol. 61 1044-1053
[10]  
Jankovic J(2006)Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study Mov. Disord. 21 343-353
12345678910